US2021347840A1PendingUtilityA1

Compositions and methods for treating heart failure in diabetic patients

63
Assignee: ZENSUN SHANGHAI SCIENCE & TECH CO LTDPriority: Oct 8, 2012Filed: Dec 22, 2020Published: Nov 11, 2021
Est. expiryOct 8, 2032(~6.2 yrs left)· nominal 20-yr term from priority
Inventors:Mingdong Zhou
A61K 38/18C13K 13/002C13K 13/007A61P 9/10C07K 14/4756A61K 38/1883A61P 9/04A61P 3/10A61P 9/00
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides the use of neuregulin protein for the preparation of medication for preventing, treating or delaying heart failure in humans and methods for preventing, treating or delaying heart failure in humans using said medication.

Claims

exact text as granted — not AI-modified
1 .- 10 . (canceled) 
     
     
         11 . A composition comprising neuregulin, wherein the composition is suitable for use in preventing, treating or delaying cardiac complications in a diabetic patient. 
     
     
         12 . The composition of  claim 11 , wherein the neuregulin is neuregulin-1. 
     
     
         13 . The composition of  claim 11 , wherein the neuregulin protein comprises of EGF-like domain of neuregulin-1β. 
     
     
         14 . The composition of  claim 11 , wherein the neuregulin comprises of SEQ ID NO: 1.

Join the waitlist — get patent alerts

Track US2021347840A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.